- NexgenRx (TSXV:NXG) grew revenue by more than 20 per cent in Q2 2026, while nearly tripling net income and nearly doubling adjusted EBITDA, reflecting resilient demand, expanded client relationships and improved operational efficiency driven by AI integrations.
- NexgenRx is Canada’s only independent full-service third-party administrator and technology solutions provider.
- The micro-cap technology stock last traded at C$0.55, adding 48.65 per cent year-over-year and more than 100 per cent since 2024.
NexgenRx (TSXV:NXG) grew revenue by more than 20 per cent in Q2 2026, while nearly tripling net income and nearly doubling adjusted EBITDA, reflecting resilient demand, expanded client relationships and improved operational efficiency driven by AI integrations.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Financial highlights
- Revenue of C$5.16 million, up by 20.8 per cent year over year (YoY), thanks to higher transaction volumes.
- Gross profit of C$4.42 million.
- Net income of C$993,095, nearly tripling from C$353,521 YoY.
- EBITDA of C$1.21 million, up by 92.5 per cent YoY.
- Cash position of C$3.6 million to support future growth initiatives.
The quarter follows a stellar Q1 and 2025, which also saw the company translate strong demand into top and bottom-line growth, building further conviction for the remainder of the year.
Dividend
NexgenRx will pay out a C$0.005 dividend on August 31 to common share and series 1 preferred shareholders of record as of August 28, 2026.
Leadership commentary
“Our exemplary Q2 results continue to underscore the scalability of our business model, the effectiveness of our growth strategy and our ongoing ability to generate strong operating cash flow while delivering sustainable, profitable growth,” Ron Loucks, President and Chief Executive Officer of NexgenRx, said in Thursday’s news release. “As we enter the second half of 2026, management remains optimistic about the opportunities ahead. We will continue investing in technology, artificial intelligence and process automation, while pursuing initiatives that enhance customer experience, improve operational scalability and expand our market presence. Supported by a strong balance sheet, a dedicated team and a disciplined approach to execution, management believes that the company is well-positioned to build on its momentum and continue delivering sustainable growth and long-term value for our shareholders.”
About NexgenRx
NexgenRx is Canada’s only independent full-service third-party administrator and technology solutions provider. Proprietary SaaS solutions on offer, catering primarily to pension plans, insurers, dental providers and pharmaceutical companies, include front-end, eligibility, enrolment, hour bank and mobile access, as well as claims adjudication and full provider network coverage.
NexgenRx stock (TSXV:NXG) last traded at C$0.55, adding 48.65 per cent year-over-year and more than 100 per cent since 2024.
Join the discussion: Find out what investors are saying about this profitable micro-cap technology stock on the NexgenRx Inc. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.